GSTP1 polymorphism predicts treatment outcome and toxicities for breast cancer

• Published in: Oncotarget 2017-09, Vol.8 (42), p.72939-72949
• Main Authors: Ma, Jie, Zhu, Shao-Liang, Liu, Yang, Huang, Xiang-Yang, Su, Dan-Ke
• Format: Article
• Language: English
• Subjects: Meta-Analysis
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.18513

This study aimed to investigate the association of the gene polymorphism with the outcomes and toxicities of treatments in breast cancer. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for the association of polymorphism with tumour response and toxicities, and the hazard ratios (HRs) and 95% CIs were calculated for the association between polymorphism and overall survival (OS). The statistical analysis showed that the polymorphism was not associated with tumour response or OS. A significant increase in the incidence of toxicities was observed (GA . AA OR = 1.45, 95% CI = 1.04-2.01, = 0.028; GG . AA OR = 1.47, 95% CI = 1.03-2.10, = 0.036; recessive model OR = 1.54, 95% CI = 1.13-2.09, = 0.006; and allele model OR = 1.35, 95% CI = 1.07-1.71, = 0.011), especially in the chemotherapy ± surgery group (GA . AA OR = 1.64, 95% CI = 1.05-2.56, = 0.030; recessive model OR = 1.72, 95% CI = 1.17-2.54, = 0.006; and allele model OR = 1.57, 95% CI = 1.11-2.21, = 0.010). Our results indicate that the polymorphism may be associated with increased toxicity, especially in patients treated with chemotherapy ± surgery.